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Mutations in BRCA1, BRCA2, and 
PALB2, and a panel of 50 cancer-
associated genes in pancreatic 
ductal adenocarcinoma
Shoko Takeuchi1,2, Manami Doi1,3, Naoki Ikari1,2, Masakazu Yamamoto1 & Toru Furukawa  2,4,5
Mutations in genes of the breast cancer susceptibility gene (BRCA) pathway, namely, BRCA1, BRCA2, 
and PALB2, can provide useful information for the efficacy of platinum-based or poly ADP-ribose 
polymerase inhibitors chemotherapeutic regimens. Pancreatic ductal adenocarcinoma (PDAC) is an 
important target for such precision chemotherapies because of its dismal prognosis. We analyzed 
mutations in the entire coding regions of the BRCA pathway genes, expression of breast cancer 2 
(BRCA2), and mutations in hotspots of 50 cancer-associated genes in 42 surgically resected PDACs, and 
evaluated their associations with clinicopathological features. We identified 13 rare germline mutations 
in the BRCA pathway genes; 68 somatic mutations in KRAS, TP53, SMAD4, CDKN2A, GNAS, SMARCB1, 
and RB1; and 2 germline variations in MLH1. Among them, BRCA2S2148fs was known to be pathogenic. 
BRCA2R18H and BRCA2G2044V were enriched in tumor tissues. BRCA2K799R and BRCA2R2964T were novel 
germline variations. Patients harboring potentially deleterious mutations in the BRCA pathway genes 
showed significantly better prognosis than those with benign mutations or no mutation. These results 
indicate that rare germline variations in BRCA pathway genes could be found more frequently than 
previously anticipated and, more importantly, potentially deleterious mutations of them could be a 
favorable prognostic factor in patients with resectable PDACs.
In 2016, pancreatic cancer was the fourth leading cause of cancer death in Japan, as was the case in Western coun-
tries, and its incidence and mortality are continuously increasing. Pancreatic ductal adenocarcinoma (PDAC), 
a common type of pancreatic cancer, is one of the most fatal malignancies, with a 5-year overall survival of less 
than 10% (Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan; https://
ganjoho.jp/reg_stat/statistics/stat/index.html), which has remained unchanged despite many decades of research. 
Although the most effective treatment for PDAC is surgical resection, it is often diagnosed at an advanced stage, 
and curative resection is not possible. Control of locally advanced tumors or metastases is critical to improve 
treatment response of advanced PDACs. Therefore, it is vital to understand the complex genotypes of such 
advanced tumors.
In the last decade, genomic analyses of PDACs have been extensively conducted, and have confirmed that 
KRAS, CDKN2A, TP53, and SMAD4 are commonly and somatically mutated genes1,2. Moreover, mutations in 
genes involved in the breast cancer susceptibility gene (BRCA) pathway, namely, BRCA1, BRCA2, and PALB2, 
have been uncovered in a subset of PDACs. BRCA pathway-mutated PDACs are presumably defective for DNA 
double-strand break repair, and may be particularly vulnerable to chemotherapies with platinum-based antican-
cer drugs or poly ADP-ribose polymerase (PARP) inhibitors. Therefore, investigating the molecular epidemi-
ological and clinicopathological characteristics of BRCA pathway-mutated PDACs is important for designing 
a therapeutic strategy for pancreatic cancer. However, data on BRCA pathway-mutated PDACs continue to be 
lacking. PDACs with familial predisposition, which is known as familial pancreatic cancer, show BRCA pathway 
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mutations as one of the most common germline mutations3. On the other hand, sporadic PDACs harbor BRCA 
pathway mutations relatively scarcely; the prevalence of mutations in BRCA2 in sporadic PDACs has been 
reported as 3.6% to 7%4,5. The data on the prevalence of BRCA1 and PALB2 mutations are more limited, but 
these prevalences have been reported at an even lower rate (<3%)6. Additionally, data on mutations of common 
oncogenes and tumor suppressor genes in BRCA pathway-mutated PDACs and their clinicopathological charac-
teristics remain limited and unclear.
In this study, we aimed to analyze mutations in BRCA pathway genes as well as 50 cancer-associated genes 
concurrently in apparently sporadic surgically resected PDACs to evaluate molecular epidemiological and clin-
icopathological characteristics in BRCA pathway-mutated PDACs.
Results
Mutations in BRCA pathway genes in PDACs. Studied were 42 patients with histopathologically con-
firmed PDACs that were surgically resected between 2007 and 2014 at the Tokyo Women’s Medical University 
Hospital whose frozen tissue samples were available. Clinicopathological features of the patients are listed in 
Supplementary Table S1. Among them, 5 cases were found to have a family history of pancreatic cancer, with 4 
cases that met the definition of familial pancreatic cancer, i.e., two first-degree relatives with PDAC3. Therefore, 
this study cohort consisted of 38 sporadic cases and 4 familial cases.
We performed targeted sequencing analyses of all coding exons of BRCA1, BRCA2, and PALB2, as well as 
sequencing mutational hotspots of 50 cancer-associated genes (Supplementary Table S2) in the 42 PDAC tumors 
with paired normal tissues using a next-generation sequencing platform. We obtained sequencing data at an aver-
age read depth of 1,043 (range 380–2,841) per amplicon. In data analysis, we collected nonsynonymous somatic 
mutations as well as nonsynonymous germline variations for which frequencies in the Exome Aggregation 
Consortium (ExAC) database7 were less than 1% (Supplementary Table S3).
We identified 13 mutations in BRCA pathway genes in 12 (28.6%) of the 42 PDACs, all of which were rare 
germline mutations including 11 in BRCA2, 1 in BRCA1, and 1 in PALB2 (Tables 1 and S4). Among these 13 
mutations, 2 germline BRCA2 mutations, BRCA2K799R and BRCA2R2964T, seemed to be novel mutations, because 
these variants were unreported in any public databases, including 1000 Genome, ExAC, dbSNP, and ESP6500. 
The germline variation BRCA1M1628T was found in a patient with a family history of pancreatic cancer (Case 42). 
The other 4 patients with a family history of pancreatic cancer did not harbor any BRCA pathway mutations. One 
patient (Case 11) harbored multiple germline mutations: BRCA2K322Q and BRCA2P3292L. We could not determine 
whether these mutations were biallelic compound mutations or not. We did not find any somatic mutation in the 
BRCA pathway genes in our cohort.
We examined predicted functional effects of all the 13 identified mutations in BRCA pathway genes using 
online prediction programs, namely, PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.
org/), and ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/). Seven of the 13 mutations were predicted as at least 
possibly damaging by SIFT and/or Polyphen-2. By ClinVar, 1 mutation was regarded as pathogenic, 7 as being 
of uncertain significance or conflicting interpretations of pathogenicity, and 3 as benign. The remaining were 
“no information” in ClinVar (Table 1). The pathogenic mutation was a frameshift mutation, BRCA2S2148fs. On 
the other hand, we found that some mutations, namely, BRCA2R18H and BRCA2G2044V, were apparently enriched 
in tumor cells, which was evidenced by increasing mutant allele frequencies in tumor tissue compared to paired 
normal tissue (Table 1). This apparent enrichment in tumor tissues suggests that these mutations may be selected 
Gene Status Coding DNA Protein dbSNP Frequency in ExAC Prediction*
Allele frequency
CaseTumor Normal
BRCA1 germline c.4883T > C p.M1628T rs4986854 0.0015 B; T; B 0.45 0.50 Case 42
BRCA2 germline c.53G > A p.R18H rs80358762 0.00004 B; T; D 0.61 0.49 Case 29
BRCA2 germline c.551T > C p.L184P rs80358775 — C; D; D 0.41 0.45 Case 7
BRCA2 germline c.623T > G p.V208G rs80358865 0.00006 U; D; D 0.50 0.45 Case 32
BRCA2 germline c.964A > C p.K322Q rs11571640 0.00006 C; D; D 0.55 0.56 Case 11
BRCA2 germline c.1744A > C p.T582P rs80358457 0.0002 C; D; D 0.46 0.49 Case 6
BRCA2 germline c.2350A > G p.M784V rs11571653 0.0003 B; T; B 0.59 N.A.** Case 19
BRCA2 germline c.2396A > G p.K799R — — N; T; B 0.50 0.50 Case 28
BRCA2 germline c.6131 G > T p.G2044V rs56191579 0.00004 C; T; B 0.72 0.53 Case 2
BRCA2 germline c.6444_6445del p.S2148fs rs80359592 — P; N; N 0.45 0.50 Case 24
BRCA2 germline c.8891G > C p.R2964T — — N; D; D 0.48 0.47 Case 35
BRCA2 germline c.9875C > T p.P3292L rs56121817 0.00007 C; D; PD 0.38 0.51 Case 11
PALB2 germline c.2228A > G p.Y743C rs141749524 0.0001 C; T; B 0.50 0.50 Case 3
Table 1. Mutations in BRCA pathway genes in pancreatic ductal adenocarcinoma. *Predictions are noted 
in the order of ClinVar, SIFT and PolyPhen-2, and abbreviations are B, benign; C, conflicting interpretations 
of pathogenicity; D, damaging; N, no information; P, pathogenic; PD, possibly damaging; T, tolerant; and 
U, uncertain significance. **N.A., not available because existence of this variation was confirmed by Sanger 
sequencing.
www.nature.com/scientificreports/
3SCIenTIfIC RepoRtS |  (2018) 8:8105  | DOI:10.1038/s41598-018-26526-x
for and confer some advantages upon cancer phenotypes, which indicates a likely pathogenicity, even though they 
were predicted to be benign for the former and conflicting interpretation of pathogenicity for the latter.
Mutations in hotspots of 50 cancer-associated genes. In analyses of hotspots of 50 cancer-associated 
genes, we identified somatic mutations in 32 hotspots and a germline mutation in 1 hotspot. In the examined 42 
PDACs, 37 (88.1%) harbored somatic mutations in KRAS; 14 (33.3%) in TP53; 7 (16.7%) in SMAD4; 6 (14.3%) in 
GNAS; 2 (4.8%) in CDKN2A; 1 (2.4%) in SMARCB1; and 1 (2.4%) in RB1 (Tables 2 and S4). These results indicate 
that mutations in KRAS, TP53, SMAD4, and CDKN2A, the four well-known genes frequently mutated in PDACs, 
were also prevalent in the current cohort at a rate almost coinciding with published reports8,9, although some 
mutations, i.e., TP53Q104fs (c.311_318del), SMAD4H105fs (c.316dupA), and SMAD4V409fs (c.1227_1228del), seemed 
to be novel, as they were unreported in the Catalogue of Somatic Mutations in Cancer (COSMIC; http://cancer.
sanger.ac.uk/cosmic) database. Mutations in GNAS were found in 6 PDACs, which suggested that these PDACs 
were associated with intraductal papillary mucinous neoplasms (IPMNs), because GNAS mutations are known 
to be exclusive to IPMNs among the diverse pancreatic neoplasms10–12. Actually, they contained cystically dilated 
ducts with papillary dysplastic cells close to solid invading tumors (Fig. 1).
We detected a germline mutation in MLH1, MLH1V143D, in 2 independent patients. This mutation has been 
reported as a germline variation found in a family with Lynch syndrome13. Therefore, we were curious whether 
these patients in our cohort might fulfill criteria for Lynch syndrome13, and indeed found that 1 of the patients 
had a past history of colon cancer and one first-degree relative with rectal cancer, although the detailed clinical 
and family information sufficient for assessing Lynch syndrome was not available. We examined the histology of 
these patients’ PDACs to determine whether they showed the medullary phenotype that is often seen in PDACs 
with the mismatch repair deficiency14; however, the tissues showed a histology of usual ductal adenocarcinoma 
with dense stromal fibrosis (Fig. 1). These patients did not harbor any BRCA pathway mutations.
Gene Status Mutation Coding DNA Protein COSMIC ClinVar N*
KRAS somatic missense c.35G > A p.G12D COSM521 pathogenic 16
KRAS somatic missense c.35G > T p.G12V COSM520 pathogenic 10
KRAS somatic missense c.34G > C p.G12R COSM518 pathogenic 7
KRAS somatic missense c.34G > T p.G12C COSM516 pathogenic 2
KRAS somatic missense c.35G > C p.G12A COSM522 pathogenic 1
KRAS somatic missense c.182A > G p.Q61R COSM1158660 pathogenic 1
TP53 somatic missense c.844C > T p.R282W COSM3378339 pathogenic 2
TP53 somatic nonsense c.916C > T p.R306X COSM3388168 pathogenic 1
TP53 somatic missense c.832C > G p.P278A COSM3717626 likely pathogenic 1
TP53 somatic missense c.824G > A p.C275Y COSM2744531 likely pathogenic 1
TP53 somatic missense c.817C > T p.R273C COSM3355991 pathogenic 1
TP53 somatic inframe deletion c.764_766del p.I255_T256del COSM1480062 — 1
TP53 somatic missense c.733G > A p.G245S COSM3356965 pathogenic 1
TP53 somatic frameshift deletion c.723del p.S241fs COSM2744618 — 1
TP53 somatic missense c.659A > G p.Y220C COSM99718 pathogenic 1
TP53 somatic missense c.524G > A p.R175H COSM3355994 pathogenic 1
TP53 somatic missense c.518T > C p.V173A COSM1630438 likely pathogenic 1
TP53 somatic missense c.413C > T p.A138V COSM288785 — 1
TP53 somatic frameshift deletion c.311_318del p.Q104fs — — 1
SMAD4 somatic frameshift insertion c.316dupA p.H105fs — — 1
SMAD4 somatic missense c.326T > G p.L109R COSM5196465 — 1
SMAD4 somatic missense c.1051G > T p.D351Y COSM1151549 — 1
SMAD4 somatic missense c.1081C > A p.R361S COSM14151 pathogenic 1
SMAD4 somatic frameshift deletion c.1227_1228del p.V409fs — — 1
SMAD4 somatic nonsense c.1333C > T p.R445X COSM14096 pathogenic 1
SMAD4 somatic frameshift insertion c.1587dupA p.L529fs COSM5945985 pathogenic 1
CDKN2A somatic nonsense c.172C > T p.R58X COSM1624870 — 1
CDKN2A somatic nonsense c.262G > T p.E88X COSM12512 likely pathogenic 1
GNAS somatic missense c.601C > T p.R201C COSM27887 pathogenic 3
GNAS somatic missense c.602G > A p.R201H COSM94388 pathogenic 3
SMARCB1 somatic missense c.215C > A p.T72K — — 1
RB1 somatic nonsense c.958C > T p.R320X COSM1152653 pathogenic 1
MLH1 germline missense c.428T > A p.V143D COSM26085 likely pathogenic 2
Table 2. Somatic and germline mutations in 50 cancer associated genes in pancreatic ductal adenocarcinoma. 
*N denotes number of cases.
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Expression of breast cancer 2 (BRCA2) protein. Next, we investigated the expression of BRCA2 in the 
42 cases by immunohistochemistry. We graded the expression in cancer cells as retained or reduced by comparing 
their expression with that in adjacent normal ducts, acini, or islet cells. The expression of BRCA2 was observed in 
both nuclei and cytoplasms, and as reduced in 7 (16.7%) of the 42 analyzed samples (Fig. 2). There was no appar-
ent difference between nuclear staining and cytoplasmic staining in this examined series. When we compared 
BRCA2 expression and BRCA2 genotype, we found that 2 of the 7 reduced expression cases harbored mutant 
alleles, and the remaining 5 cases had wild-type BRCA2, in which the reduced expression was not significantly 
associated with mutation in BRCA2 (Table 3). The PDAC tissue that harbored the frameshift germline variation, 
BRCA2S2148fs, showed retained expression of BRCA2.
Association between BRCA pathway mutations and clinicopathological features. To know clin-
icopathological significances of BRCA pathway mutations in PDACs, we divided our cohort into two subcohorts 
in several ways by their genetic state and compared statistically. We found that patients with potentially deleteri-
ous mutations in BRCA pathway genes, i.e., mutations with predictions other than benign by ClinVar including 
pathogenic, conflicting, uncertain, or no information, showed significantly better prognosis than those without 
mutations or with benign mutations by ClinVar, in which the 5-year overall survival was 68.6% in the former and 
19.2% in the latter (p = 0.031 by logrank test; Fig. 3 and Table 3). This trend was confirmed in a stage-specific 
manner, i.e., patients with stage III PDAC showed distinct prognosis according to the BRCA pathway genotype 
(Supplementary Fig. S1). Other clinicopathological features including age, T stage (local tumor invasion), N stage 
(lymph node metastasis), tumor stage, histology, recurrence, previous cancer history, family history including 
familial pancreatic cancer were not specifically associated with the BRCA genotypes (Table 3). On the other hand, 
comparison of prognosis between patients with BRCA mutations including the benign mutations and those with-
out mutation did not show any significant difference. We also found no significant association between BRCA 
pathway mutations and mutations in KRAS, CDKN2A, TP53, SMAD4, or GNAS (Supplementary Table S5). In 
41 patients with available information in our cohort, 39 patients received adjuvant chemotherapies with gemcit-
abine, S-1 (tegafur, gimeracil, and oteracil), paclitaxel, cisplatin, and erlotinib. There was no significant difference 
in administered chemotherapeutic drugs between the patients with potentially deleterious BRCA pathway muta-
tions and those without BRCA pathway mutations or mutations with the benign prediction although cisplatin 
was administered for 2 patients who had no BRCA pathway mutations in their tumors. We also evaluated the 
association between expression of BRCA2 and clinicopathological features; however, BRCA2 expression was not 
significantly associated with any clinicopathological features (Table 3).
Figure 1. Histopathological images of examined pancreatic ductal adenocarcinomas. The tissue of Case 14 
with the somatic mutation of GNAS showed cystically dilated ducts with papillary dysplastic cells (a) expressing 
mucin 5AC (c) close to solid invading tumors (b) the higher magnification image of inset in (a)), which 
indicates that this carcinoma was associated with IPMN. The tissue of Case 30 with the germline mutation of 
MLH1 showed pathological findings of usual ductal adenocarcinoma with dense stromal fibrosis (d). (a,b and 
d), hematoxylin and eosin staining, and (c) indirect immunohistochemical staining. Original magnification, 
×40 (a) ×100 (b) ×40 (c) and ×40 (d).
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Discussion
In this study, we detected 13 rare germline mutations in BRCA pathway genes in 12 (28.6%) of 42 patients with 
PDAC including 11 variants of BRCA2, 1 of BRCA1, and 1 of PALB2. Some of these variations seemed to be novel. 
The prevalence of BRCA2 germline mutations in our study was one of the highest published, which could be due 
to (1) different ethnic cohorts because our cohort was consisted of Japanese patients while other published papers 
used North American cohorts4,5,15; and (2) different database for extracting the germline variations, in which we 
used ExAC7, the most reliable exome database currently available, while Grant et al. used the 1000 Genome pro-
ject, dbSNP138, and the National Heart, Lung, and Blood Institute Exome Variant Server ESP6500 data set4,5,15. 
Nevertheless, the results suggest that rare germline variations in BRCA pathway genes may be found in patients 
with PDAC relatively more frequently than previously anticipated. Hence, testing for mutations in BRCA pathway 
genes could be warranted not only in familial cases but also in apparently sporadic cases.
The germline variations detected in the BRCA pathway genes could be pathogenic, and 1 frameshift germline 
variation found in our cohort, BRCA2S2148fs, was known to be pathogenic by ClinVar. One clue suggesting path-
ogenicity is the enrichment of a mutant allele in tumor tissues. We observed such an enrichment in 2 missense 
variations in BRCA2, namely, BRCA2R18H and BRCA2G2044V. BRCA2R18H is reported in the Kathleen Cuningham 
Foundation Consortium for Research into Familial Breast Cancer (kConFab) and a Korean breast cancer patients’ 
cohort as of uncertain variance16,17. The R18 residue resides in an interaction domain between BRCA2 and the 
Figure 2. Expression of BRCA2 protein in pancreatic ductal adenocarcinomas. The tissues of Case 17 (a,b) 
and Case 19 (c,d) showed reduced expression of BRCA2 in the ductal carcinomas (arrowheads in b and d) 
in comparison with adjacent normal acinar and islet cells (arrows in b and d). The tissue of Case 29 (e,f), 
in which the enrichment of a missense mutant allele in the tumor DNA was detected, showed retained 
expression of BRCA2 in ductal carcinoma (arrowheads in f) comparable to the normal acini (an arrow in f). 
Images were hematoxylin and eosin staining (a,c and e) and the indirect immunohistochemical staining with 
diaminobenzidine as the chromogen (b,d and f). Original magnification, ×200.
www.nature.com/scientificreports/
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partner and localizer of BRCA2 encoded by PALB218. BRCA2G2044V has been found in Japanese, Korean, and 
Brazilian breast cancer patients17,19,20. The Brazilian patient had a family member with hereditary breast and 
ovarian cancer syndrome20. The G2044 residue resides within the BRCA2 repeat domain but outside of the most 
conserved region21. Foci of somatic mutations can also be a clue for pathogenicity. According to the COSMIC 
database, BRCA2 somatic mutations have been reported in glioma (BRCA2R18H), squamous cell carcinoma of the 
head and neck (BRCA2M784V), and squamous cell carcinoma of the skin (BRCA2P3292L).
Notably, the patients with potentially damaging germline mutations of BRCA pathway genes showed better 
prognosis than those with benign mutations or no mutation. On the other hand, we did not find any significant 
difference between all patients with BRCA mutations including benign mutations and those without BRCA muta-
tions. This may suggest that deleterious mutations may cause some advantageous effects in prognosis of patients 
with pancreatic cancer. Deleterious mutations of BRCA pathway genes can induce genomic instability and be a 
surrogate marker for responsiveness for platinum-based chemotherapy or PARP inhibitor6. Golan et al. reported 
that they found no prognostic difference in patients with resectable pancreatic cancer between 25 of those with 
BRCA mutations and 49 without mutations despite with a trend to increase disease free survival among the BRCA 
mutation-positive cases treated with neoadjuvant/adjuvant platinum-containing regimens22. Some reports have 
indicated a better prognosis and response to platinum-based treatment in pancreatic cancer patients with BRCA 
mutations23,24. Most of patients of our cohort received an adjuvant chemotherapy based on gemcitabine and S-1 








Wild type or benign 
mutations** Retain Reduced
BRCA2 mutation
   Mutant 8 2 — 8 2 1.00
   Wild 1 31 — 27 5
Age at operation
   Mean (range) 68 (53–79) 65 (43–87) 0.40 65 (43–87) 70 (56–77) 0.23
T***
   T1, T2 3 9 0.70 10 2 1.00
   T3, T4 6 24 25 5
N***
   N0 1 12 0.23 11 2 1.00
   N1, N2 8 21 24 5
Stage***
   0 0 0 0.44 0 0 0.52
   I 0 1 1 0
   II 0 6 5 1
   III 6 12 13 5
   IVa 3 13 15 1
   IVb 0 1 1 0
Histology 0 0 0.44
   Tubular adenocarcinoma 8 27 1.00 30 5 0.58
   other 1 6 5 2
Recurrence
   Yes 4 23 0.24 23 4 0.69
   No 5 10 12 3
Previous cancer history
   Yes 1 10 0.40 10 1 0.65
   No 8 23 25 6
Family history of any cancers
   Yes 3 18 0.45 17 4 1.00
   No 6 15 18 3
Family history of pancreatic cancer
   Yes 0 5 0.57 4 1 1.00
   No 9 28 31 6
Prognosis
   5-year overall survival 68.6% 19.2% 0.031 34.3% 0% 0.83
Table 3. BRCA pathway aberrations and clinicopathological features. *Patients with mutations predicted as 
pathogenic, conflicting, uncertain, or no information by ClinVar. **Patients with mutations predicted as benign 
by Clinvar or those without mutations. ***According to Japan Pancreas Society Classification (6th ed.).
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between the subcohorts, which indicated that the better survival of the subcohort of patients with potentially del-
eterious mutations was not associated with a chempotherapeutic difference. Hence we could not interpret exactly 
why the subcohort of patients showed better survivals. Nevertheless, our results may warrant a further study to 
know prognostic value of BRCA pathway mutations in patients with apparently sporadic pancreatic cancer in a 
larger cohort.
Familial pancreatic cancer is known to be associated with germline mutations in BRCA pathway genes25,26. 
Our cohort included 4 patients with familial pancreatic cancer, which is consistent with previously published 
results showing that 7–10% of PDACs correspond to familial pancreatic cancer3,25. One of these 4 patients har-
bored a germline mutation in BRCA1, BRCA1M1628T. This variation has been reported in a breast cancer patient 
with a family history of breast cancer; however, it has not been previously reported in any case of familial pancre-
atic cancer25,27,28. This variation was predicted to be benign by ClinVar.
We did not find any specific associations between BRCA pathway mutations and mutations in commonly 
mutated genes, namely, KRAS, CDKN2A, TP53, SMAD4 and GNAS. Mutations in these genes were frequently 
observed in our cohort in frequencies consistent with published results8,9. Besides KRAS and GNAS, which usu-
ally incurs missense substitutions, CDKN2A, TP53, and SMAD4 can be targets of structural variation29; therefore, 
if we could detect structural variations that could be associated with BRCA pathway mutations, there may be 
some specific associations elucidated, which is an area of further research.
There are some limitations to our study. This study was a retrospective study. The examined cohort was small 
and included only surgically resected cases. Broader sequencing analysis, such as whole-exome sequencing, may 
be needed to uncover molecular characteristics associated with BRCA pathway mutations in PDAC.
Methods
Subjects and materials. Studied were 42 patients with histopathologically confirmed PDACs surgically 
resected between 2007 and 2014 at the Tokyo Women’s Medical University Hospital whose frozen tissue sam-
ples were available. In all cases, we used frozen tissue samples of tumor and normal tissues (pancreas, spleen, or 
duodenum) obtained during surgery. We excluded patients who underwent neoadjuvant chemotherapy, because 
DNA extracted from a treated tumor could be modified by anticancer agents.
This study was approved by the Ethical Committee for genetic studies of the Tokyo Women’s Medical 
University (protocol #212). The patients analyzed gave relevant informed consent. All research was performed in 
accordance with relevant guidelines and regulations.
Tissue dissection and DNA extraction. Methanol-fixed, toluidine-blue-stained sections were prepared 
from the frozen tissue samples. Tumor and normal tissues were manually dissected and collected separately 
from the sections under microscopic guidance. Genomic DNA was extracted using a GenEluteTM Mammalian 
Genomic DNA Miniprep Kit (Sigma-Aldrich Corp., St. Louis, MO, USA) according to the manufacturer’s 
instructions.
Targeted sequencing analyses by next-generation sequencing. We performed targeted sequencing 
analyses using the Ion Torrent system (Thermo Fisher Scientific Inc., Waltham, MA, USA). The Ion AmpliseqTM 
Custom DNA panel (Thermo Fisher Scientific) was used for targeted sequencing to detect mutations in the entire 
coding regions of BRCA1, BRCA2, and PALB2, and the Ion AmpliseqTM Cancer Hotspot Panel v2 (Thermo Fisher 
Scientific) was used for targeted sequencing to examine hotspot regions of 50 oncogenes and tumor suppressor 
genes, as listed in Supplementary Table S2. In both sequencing analyses, the libraries were prepared using the 
Ion AmpliseqTM Library Kit 2.0 and Ion XpressTM Library Barcode Adaptors (Thermo Fisher Scientific). The 
constructed libraries were treated with Ion One TouchTM 2 (Thermo Fisher Scientific) and sequenced using 
Ion PGMTM sequencer (Thermo Fisher Scientific). Sequencing data were processed with Torrent Suit software 
(Thermo Fisher Scientific). All procedures were performed according to the manufacturer’s instructions.
Figure 3. Kaplan-Meier survival analyses of patients with pancreatic ductal adenocarcinomas (PDACs) 
according to mutations in the BRCA pathway genes. Nine patients with PDACs with potentially deleterious 
mutations in BRCA pathway genes, namely, BRCA1, BRCA2 and PALB2 (Mutant), and 33 patients with PDACs 
with benign mutations or without mutations in the BRCA pathway genes (Benign or wild) were compared. The 
P value was obtained by Log-rank test.
www.nature.com/scientificreports/
8SCIenTIfIC RepoRtS |  (2018) 8:8105  | DOI:10.1038/s41598-018-26526-x
Sanger sequencing. We validated the targeted sequencing data by Sanger sequencing. DNA was ampli-
fied by polymerase chain reaction (PCR) using primers listed in Supplementary Table S6 and the Accuprime 
PCR system (Thermo Fisher Scientific). Amplified products were processed with ExoSAP-IT (GE Healthcare, 
Buckinghamshire, UK) and sequenced using Bigdye Terminator and a 3130xl Genetic Analyzer (Thermo Fisher 
Scientific).
Immunohistochemistry. We evaluated the expression of BRCA2 in tumor and normal tissues by indirect 
immunohistochemical staining of paraffin-embedded tissues as described previously30. The primary antibody 
used was rabbit polyclonal anti-BRCA2 (CA1033, EMD Millipore Corp., Billerica, MA, USA) produced by using 
a carboxyl-terminal region (amino acids 3245–3418) of human BRCA2 as an immunogen. Antigen retrieval 
and dilution of antibody were performed according to the manufacturers’ instructions. Immunohistochemistry 
of mucin 5AC was performed using mouse monoclonal anti-MUC5AC antibody (NCL-MUC-5AC, Leica 
Biosystems, Mussloch, Germany) and Ventana BenchMark XT (Ventana Medical Systems, Inc., Tucson, AZ, 
USA) according to the manufacturers’ instructions.
Statistics. Clinicopathological and molecular descriptive statistics were calculated for study variables strat-
ified by BRCA pathway mutations (potentially deleterious mutations vs. wild type or benign mutations) and 
BRCA2 expression (retain vs. reduced). We used the Fisher’s exact test to compare the distribution of clinico-
pathological and molecular data because of the small sample sizes. Kaplan-Meier analysis with log-rank test was 
used to analyze survival. P values < 0.05 were considered statistically significant. All statistical analyses were 
performed using JMP 13 software (SAS Institute Inc., Cary, NC, USA).
Data availability. The data that support the findings of this study are included in this published article and 
its supplementary online information files.
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